Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Modulating potency: Physicochemical characteristics are a determining factor of TLR4-agonist nanosuspension activity.

Dowling QM, Sivananthan SJ, Guderian JA, Moutaftsi M, Chesko JD, Fox CB, Vedvick TS, Kramer RM.

J Pharm Sci. 2014 Mar;103(3):879-89. doi: 10.1002/jps.23868. Epub 2014 Jan 24.

PMID:
24464844
2.

TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses.

Fox CB, Moutaftsi M, Vergara J, Desbien AL, Nana GI, Vedvick TS, Coler RN, Reed SG.

Vaccine. 2013 Dec 2;31(49):5848-55. doi: 10.1016/j.vaccine.2013.09.069. Epub 2013 Oct 10.

PMID:
24120675
3.

Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells.

Baldwin SL, Ching LK, Pine SO, Moutaftsi M, Lucas E, Vallur A, Orr MT, Bertholet S, Reed SG, Coler RN.

J Immunol. 2013 Sep 1;191(5):2514-2525. doi: 10.4049/jimmunol.1301161. Epub 2013 Jul 31.

4.

Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cells.

Matthews K, Chung NP, Klasse PJ, Moutaftsi M, Carter D, Salazar AM, Reed SG, Sanders RW, Moore JP.

PLoS One. 2013 May 20;8(5):e63785. doi: 10.1371/journal.pone.0063785. Print 2013.

5.

Sculpting MHC class II-restricted self and non-self peptidome by the class I Ag-processing machinery and its impact on Th-cell responses.

Spencer CT, Dragovic SM, Conant SB, Gray JJ, Zheng M, Samir P, Niu X, Moutaftsi M, Van Kaer L, Sette A, Link AJ, Joyce S.

Eur J Immunol. 2013 May;43(5):1162-72. doi: 10.1002/eji.201243087. Epub 2013 Mar 5.

6.

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.

Arias MA, Van Roey GA, Tregoning JS, Moutaftsi M, Coler RN, Windish HP, Reed SG, Carter D, Shattock RJ.

PLoS One. 2012;7(7):e41144. doi: 10.1371/journal.pone.0041144. Epub 2012 Jul 19.

7.

Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells.

Schneider LP, Schoonderwoerd AJ, Moutaftsi M, Howard RF, Reed SG, de Jong EC, Teunissen MB.

Vaccine. 2012 Jun 13;30(28):4216-24. doi: 10.1016/j.vaccine.2012.04.051. Epub 2012 Apr 25.

PMID:
22542815
8.

Dissecting mechanisms of immunodominance to the common tuberculosis antigens ESAT-6, CFP10, Rv2031c (hspX), Rv2654c (TB7.7), and Rv1038c (EsxJ).

Arlehamn CS, Sidney J, Henderson R, Greenbaum JA, James EA, Moutaftsi M, Coler R, McKinney DM, Park D, Taplitz R, Kwok WW, Grey H, Peters B, Sette A.

J Immunol. 2012 May 15;188(10):5020-31. doi: 10.4049/jimmunol.1103556. Epub 2012 Apr 13.

9.

Targeting OX40 promotes lung-resident memory CD8 T cell populations that protect against respiratory poxvirus infection.

Salek-Ardakani S, Moutaftsi M, Sette A, Croft M.

J Virol. 2011 Sep;85(17):9051-9. doi: 10.1128/JVI.00619-11. Epub 2011 Jun 29.

10.

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.

Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, Laughlin EM, Duthie MS, Fox CB, Carter D, Friede M, Vedvick TS, Reed SG.

PLoS One. 2011 Jan 26;6(1):e16333. doi: 10.1371/journal.pone.0016333.

11.

Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens.

Moutaftsi M, Tscharke DC, Vaughan K, Koelle DM, Stern L, Calvo-Calle M, Ennis F, Terajima M, Sutter G, Crotty S, Drexler I, Franchini G, Yewdell JW, Head SR, Blum J, Peters B, Sette A.

Future Microbiol. 2010 Feb;5(2):221-39. doi: 10.2217/fmb.09.110. Review.

12.

Definition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens.

Sette A, Grey H, Oseroff C, Peters B, Moutaftsi M, Crotty S, Assarsson E, Greenbaum J, Kim Y, Kolla R, Tscharke D, Koelle D, Johnson RP, Blum J, Head S, Sidney J.

Vaccine. 2009 Dec 30;27 Suppl 6:G21-6. doi: 10.1016/j.vaccine.2009.10.011. Review.

13.

Correlates of protection efficacy induced by vaccinia virus-specific CD8+ T-cell epitopes in the murine intranasal challenge model.

Moutaftsi M, Salek-Ardakani S, Croft M, Peters B, Sidney J, Grey H, Sette A.

Eur J Immunol. 2009 Mar;39(3):717-22. doi: 10.1002/eji.200838815.

14.

OX40 drives protective vaccinia virus-specific CD8 T cells.

Salek-Ardakani S, Moutaftsi M, Crotty S, Sette A, Croft M.

J Immunol. 2008 Dec 1;181(11):7969-76.

15.

Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities.

Sette A, Moutaftsi M, Moyron-Quiroz J, McCausland MM, Davies DH, Johnston RJ, Peters B, Rafii-El-Idrissi Benhnia M, Hoffmann J, Su HP, Singh K, Garboczi DN, Head S, Grey H, Felgner PL, Crotty S.

Immunity. 2008 Jun;28(6):847-58. doi: 10.1016/j.immuni.2008.04.018.

16.

Dissociation between epitope hierarchy and immunoprevalence in CD8 responses to vaccinia virus western reserve.

Oseroff C, Peters B, Pasquetto V, Moutaftsi M, Sidney J, Panchanathan V, Tscharke DC, Maillere B, Grey H, Sette A.

J Immunol. 2008 Jun 1;180(11):7193-202.

17.

Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely distinct from those targeted by CD8+ T cell responses.

Moutaftsi M, Bui HH, Peters B, Sidney J, Salek-Ardakani S, Oseroff C, Pasquetto V, Crotty S, Croft M, Lefkowitz EJ, Grey H, Sette A.

J Immunol. 2007 Jun 1;178(11):6814-20.

18.

A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus.

Moutaftsi M, Peters B, Pasquetto V, Tscharke DC, Sidney J, Bui HH, Grey H, Sette A.

Nat Biotechnol. 2006 Jul;24(7):817-9. Epub 2006 Jun 11.

PMID:
16767078
20.

Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells.

Moutaftsi M, Mehl AM, Borysiewicz LK, Tabi Z.

Blood. 2002 Apr 15;99(8):2913-21.

Supplemental Content

Loading ...
Support Center